Business - Briefly   

Ranbaxy ties up with U.S. firm

MUMBAI: Ranbaxy Laboratories has entered into a strategic partnership with the U.S.-based Invagen Pharmaceuticals for marketing Zonisamide Capsules, which are used for the treatment of epilepsy, in the U.S. market. Under the agreement products would be developed and submitted for approval to the USFDA. Ranbaxy Pharmaceuticals Inc would market the products under the company's label, says a release.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Textile units invited to invest in Kazakh's SEZ
TNPL to expand capacity
Cummins to increase sourcing from India
L&T Infotech initial public offering in 2008
BSE/NSE Notes
Merck gets licence for cervical cancer vaccine
Sensex rebounds
Rupee regains strength
Exchange rates
Bullion rates
Centre proposes Special Purpose Coffee Fund
Inflation falls marginally
ICICI hikes interest rates
Reliance approaches TDSAT
Yes Bank to advise Agri Ministry
EU to rule on Arcelor-Severtsal merger
Bureau Veritas opens office
Repco Bank revises deposit rates
Ranbaxy ties up with U.S. firm
LG Electronics' Ranjangaon unit on stream
UTI MF launches UTI- SPrEAD Fund
Wyeth pays Rs. 25 per share
Two RBI departments get BS certification
Air Deccan opens bookings for Airbus services
Kinetic launches `Stryker' in Chandigarh
UTI MF launches UTI- SPrEAD Fund
Pantaloon to promote joint venture
GATI deploys Cisco's WAN

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu